Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 and Fruquintinib with SCRT vs Standard Therapy in Liver-Metastatic Colorectal Cancer
NCT07353268Phase 2Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iparomlimab + tuvorralimab in colorectal cancer (CRC) (2 arms). Primary endpoint: Progression Free Survival at 6 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvorralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07353268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353268.